Clene (FRA:84C) ROCE % : -98.11% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clene ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Clene's annualized ROCE % for the quarter that ended in Dec. 2023 was -98.11%.

Clene ROCE % Historical Data

The historical data trend for Clene's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene ROCE % Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-152.11

-52.60

-16.97

-63.30

-153.53

Clene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial												-1.90	-158.66	-225.20	-9.26	-98.11

Clene ROCE % Calculation

Clene's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-41.215	/	( ( (42.001 - 13.081)	+	(47.997 - 23.228) )	/ 2 )
	=	-41.215	/	( (28.92	+	24.769)	/ 2 )
	=	-41.215	/	26.8445
	=	-153.53 %

Clene's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-32.912	/	( ( (56.626 - 14.306)	+	(47.997 - 23.228) )	/ 2 )
	=	-32.912	/	( ( 42.32	+	24.769 )	/ 2 )
	=	-32.912	/	33.5445
	=	-98.11 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Clene (FRA:84C) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Clene ROCE % Related Terms

Thank you for viewing the detailed overview of Clene's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clene (FRA:84C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (FRA:84C) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CLNN:USA

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Clene (FRA:84C) Headlines

No Headlines